Victor H Engelhard

This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University of Virginia Patent Foundation, Rijksuniversiteit Te Leiden, The University of Birmingham. Active years: 1998-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Victor H Engelhard. Retrieved from https://idiyas.com/inventor/victor-h-engelhard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 4)

% Patents Active = 85.7

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 40(Granted Patents)

Location History:

Charlottesville, VA (US) (1998 - 2007)
Crozet, VA (US) (2011 - 2024)

Company Filing History:

9 out of 1,044

University of Virginia Patent Foundation

patents

4 out of 14

Rijksuniversiteit Te Leiden

patents

2 out of 125

The University of Birmingham

patents

4. 1 out of 3,801

Johns Hopkins University

patents

5. 1 out of 1

Rijsuniversiteit Te Leiden

patent

where one patent can have more than one assignee

Years Active: 1998-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12042530 - Target peptides for immunotherapy and diagnostics (2024-07-23),

2. 11987613 - Isolated T cell receptors and methods of use therefor (2024-05-21),

3. 10654908 - Isolated T cell receptors and methods of use therefor (2020-05-19),

4. 9561266 - Target peptides for immunotherapy and diagnostics (2017-02-07),

5. 9345755 - Composition and methods for treating melanoma (2016-05-24),

6. 9279011 - Phosphopeptides as melanoma vaccines (2016-03-08),

7. 8012484 - Method of treating ischemia reperfusion injury by inhibiting NKT cell activity (2011-09-06),

8. 7205119 - HA-1 antigen (2007-04-17),

9. 7019112 - Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor (2006-03-28),

10. 7008922 - H-Y antigen (2006-03-07),

11. 6878375 - HA-1 antigen (2005-04-12),

12. 6558671 - Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor (2003-05-06),

13. 6521598 - H-Y antigen (2003-02-18),

14. 5770201 - HA-2 antigenic peptide (1998-06-23),

Title: Victor H Engelhard: Innovator in Immunotherapy

Introduction

Victor H Engelhard, a prominent inventor based in Crozet, VA, has made significant contributions to the field of immunotherapy through his innovative research and development. With a total of 14 patents to his name, Engelhard's work focuses on targeting peptides that hold potential for cancer treatment and diagnostics.

Latest Patents

Among his notable inventions are his latest patents, which include "Target peptides for immunotherapy and diagnostics". This patent describes a set of target peptides presented by various HLA molecules on the surface of disease cells, designed to stimulate an immune response against proliferative diseases such as cancer. The applications of these peptides are multi-faceted, serving as immunotherapeutics in adoptive T cell therapy, functioning as vaccines, aiding in antibody recognition of tumor boundaries in surgical pathology samples, and acting as biomarkers for early disease detection. Engelhard's other significant patent, "Isolated T cell receptors and methods of use therefor," deals with isolated T cell receptors that bind to phosphopeptide-HLA-A2 complexes, highlighting innovative methods for their application in therapeutic compositions and kits.

Career Highlights

Engelhard has established a remarkable career, contributing his expertise to esteemed institutions, including the University of Virginia and Rijksuniversiteit Te Leiden. His work has not only advanced scientific understanding but also paved the way for practical applications in medicine.

Collaborations

Throughout his career, Engelhard has collaborated with notable professionals such as Donald F Hunt and Jeffrey Shabanowitz. These partnerships have enriched his research and have helped drive the innovative technologies that stem from his inventions.

Conclusion

Victor H Engelhard stands out as a leading inventor in the field of immunotherapy, pushing the boundaries of what is possible in cancer treatment and detection. His dedicated research and numerous patents reflect a commitment to innovation that could potentially transform healthcare and improve patient outcomes.

Profile summary based on public USPTO records.